Cycle Pharmaceuticals has partnered with UpScriptHealth to provide an online telehealth service for people in the United States diagnosed with Alkaptonuria (AKU).

AKU is a very rare disease that affects approximately 1 in 250,000 people worldwide.¹ On average, it can take six years for someone to get a diagnosis, with many visits to different specialists.² It can be hard, once diagnosed, for people to find a healthcare provider who understands what it is like to live with AKU, especially if they live far from a rare disease medical center. It can also be hard for them to get prescribed a treatment to help them slow the progression of AKU.

“After the drug was passed by the FDA in 2025, there have been some issues with [me] getting the medication. I was expecting to gain access to the medication much faster, but I didn’t truly understand how long of a process it was. There were many unexpected hoops to jump through.”

Hunter, living with AKU

Through this new telehealth service, people who have been diagnosed with AKU can now speak to a licensed AKU-trained healthcare provider online to see if treatment is suitable for them.*

To access the service, individuals must be over 18 years old, live in the United States, and already be diagnosed with AKU. They will be asked to complete an online health questionnaire before booking a virtual appointment at a time that suits them. The initial online consultation costs $35 and allows patients to explore treatment options and the next step in AKU care.

At Cycle Pharmaceuticals, we are committed to helping people living with rare diseases beyond their treatment. By working with UpScriptHealth we hope more patients will be able to access support to help them manage their condition.